Document is current
Any future updates will be listed below
-
Authors
Xue, Yingjiao
Zhu, Liang
Karan, Saumen
Locker, Joseph D.
Branch, Craig
Zhang, Jinghang
Hoang, Bang
Maianti, Juan Pablo https://orcid.org/0000-0002-7426-6958
Zhao, Hongling https://orcid.org/0000-0003-0453-2277
Schwartz, Edward L. https://orcid.org/0000-0002-0669-9292
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (RO1CA201458, RO1CA201458, P30CA13330)
- License Information
-
More Information
Article History
Received: 18 September 2023
Accepted: 4 February 2025
First Online: 22 February 2025
Competing interests
: The authors declare the following competing interests: E.S. is a consultant for Sandoz Pharmaceuticals. J.P.M. is a co-founder of Exo Therapeutics, a company focused on substrate-binding sites. The remaining authors declare no competing interests.
